Miguel Sampayo-Cordero

Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial

José Manuel Pérez-García, Marta Vaz Batista, Patricia Cortez et al. · Neuro-Oncology · 2022 · 237 citations · Full text

Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial

José Manuel Pérez-García, Géraldine Gebhart, Manuel Ruíz Borrego et al. · The Lancet Oncology · 2021 · 152 citations

Breast Oncology, Medicine, Chemotherapy De-escalation +5

Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor–Positive, <i>ERBB2</i>-Negative Advanced Breast Cancer

Antonio Llombart‐Cussac, José Manuel Pérez-García, Meritxell Bellet et al. · JAMA Oncology · 2021 · 99 citations · Full text

Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR[+])/human epidermal growth factor receptor 2-negative (HER2[-]) advanced breast cancer (ABC): PALMIRA trial.

Antonio Llombart‐Cussac, Catherine Harper‐Wynne, Antonia Perelló et al. · Journal of Clinical Oncology · 2023 · 69 citations

Breast Oncology, Pharmacotherapy, Pre-clinical Pharmacology +17

3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial

José Manuel Pérez-García, Javier Cortés, Manuel Ruíz‐Borrego et al. · The Lancet · 2024 · 69 citations

Breast Oncology, Medicine, Chemotherapy De-escalation +4